History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ?12 months prior to randomization
No history of serious digestive and/or absorptive problems, including inflammatory bowel disease and chronic diarrhea that preclude adherence to the study diet
Have inflammatory bowel disease for which the participant has used immunosuppressive agents within the last 2 years.
Active diarrhea or inflammatory bowel disease
Active or documented inflammatory disease.
Patients with history of and/or active inflammatory bowel disease.
Participants with inflammatory bowel disease
Active inflammatory or other gastrointestinal disease,
Inflammatory or chronic functional bowel disorder such as Crohn's Disease, inflammatory bowel disease, chronic diarrhea, or constipation
History of inflammatory bowel disease
History of inflammatory bowel disease
History of inflammatory bowel disease, autoimmune disease, or other connective tissue diseases
Patients with history or current diagnosis of inflammatory bowel disease are not eligible
Any condition or history of active rectal inflammatory bowel disease or other factors which might increase the risk of fistula formation;
Active inflammatory bowel disease, other bowel disease causing chronic diarrhea (defined as > 4 loose stools per day), or bowel obstruction
Inflammatory bowel disease
Patients with inflammatory bowel disease
Patients with inflammatory bowel disease
Active or prior documented inflammatory bowel disease
History of inflammatory bowel disease;
malabsorption syndromes such as celiac disease, cystic fibrosis, inflammatory bowel disease, systemic sclerosis, and carcinoid syndrome
History of hemorrhagic diarrhea, inflammatory bowel disease or active uncontrolled peptic ulcer disease; (concomitant therapy with ranitidine or its equivalent and/or omeprazole or its equivalent is acceptable); history of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility
Inflammatory bowel disease
Patients with complete bowel obstruction or who are at high risk for gastrointestinal (GI) perforation or severe hemorrhage and patients with inflammatory bowel disease
Clinical contraindication to stereotactic body radiotherapy as determined by the investigator (e.g., active systemic sclerosis, active inflammatory bowel disease if bowel is within radiation field)
Poorly controlled inflammatory bowel disease
History of inflammatory bowel disease
Uncontrolled inflammatory bowel disease
Autoimmune disease such as scleroderma, lupus, or inflammatory bowel disease
History of autoimmune disease such as scleroderma, lupus, and inflammatory bowel disease
Patients with active inflammatory bowel disease
Patients with inflammatory bowel disease
History of inflammatory bowel disease
Has active or prior inflammatory bowel disease or primary immunodeficiency
There are no exclusions due to co-morbid disease or illnesses except for patients who carry a diagnosis of Inflammatory Bowel Disease that has been active within the last year
History of inflammatory bowel disease
History of or ongoing inflammatory bowel disease
Any medical condition that would be a contra-indication to radiation therapy, such as inflammatory bowel disease
Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)
No standard contraindications to radiation therapy including prior significant radiation therapy, inflammatory bowel disease, irritable bowel syndrome or collagen vascular disease
Patients with significantly diseased or obstructed gastrointestinal tract that could interfere with absorption of oral medication, including inflammatory or chronic functional bowel disorder, such as Crohn disease, inflammatory bowel disease, chronic diarrhea, or constipation
History of inflammatory bowel disease requiring ongoing therapy
DONOR: History of or symptoms consistent with inflammatory bowel disease or a serious autoimmune disorder
Inflammatory bowel disease
Active inflammatory bowel disease
Patients with history of inflammatory bowel disease, or who require steroid or cytotoxic therapy for collagen vascular disease
Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)
Patients with active inflammatory bowel disease
The participant has a history of inflammatory bowel disease or Crohn's disease requiring medical intervention within 12 months.
Patient must not have a history of inflammatory bowel disease requiring pharmacological and/or surgical intervention within the 12 months prior to randomization
Patient must have no active inflammatory bowel disease
Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease.
Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or any upper gastrointestinal surgery including gastric resection.
Ongoing inflammatory bowel disease
History of inflammatory bowel disease
Active inflammatory bowel disease or chronic diarrhea, short bowel syndrome, or upper gastrointestinal surgery including gastric resection
History of inflammatory bowel disease or active bowel inflammation
History of inflammatory bowel disease, prior bowel surgeries (or colostomy) for any reason, or prior partial/radical cystectomy for any reason
have active gastrointestinal (GI) disease characterized by inflammatory bowel disease, malabsorption syndrome, or frequent Grade 2 or more diarrhea
Inflammatory bowel disease
Have a history of inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) ?12 months prior to randomization.
Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)
History of chronic inflammatory bowel disease or Crohn's disease requiring medical intervention (immunomodulatory or immunosuppressive medications or surgery) =< 12 months prior to randomization
Active inflammatory bowel disease
Inflammatory bowel disease
Inflammatory bowel disease or connective tissue disease requiring medical management
History of autoimmune disease, including inflammatory bowel disease
History of inflammatory bowel disease
Prior history of scleroderma or inflammatory bowel disease
Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)
Any chronic inflammatory bowel disease and/or chronic bowl obstruction
history of inflammatory bowel disease of the rectum;
Ongoing inflammatory bowel disease
History of autoimmune disease or known inflammatory bowel disease.
History of inflammatory bowel disease
Patients with a history of inflammatory bowel disease
Ongoing inflammatory bowel disease
Patients with history of inflammatory bowel disease or major bowel surgery
Ongoing gastrointestinal medical condition such as Crohn's disease, Inflammatory bowel disease, chronic diarrhea, or constipation
Ongoing inflammatory bowel disease
Known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Active or prior documented autoimmune, or inflammatory bowel disease, or inflammatory bowel disease. or systemic treatment for psoriasis within the past 5 years.;
Known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Ongoing inflammatory bowel disease
Active inflammatory bowel disease
Subjects with known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Patients with active inflammatory bowel disease
Known clinically significant gastrointestinal disease including, but not limited to, inflammatory bowel disease
Prior history of inflammatory bowel disease.
Patients with inflammatory bowel disease or other autoimmune conditions which might affect the radiated colon or rectum
Gastrointestinal (GI) disease with increased risk of diarrhea (e.g. inflammatory bowel disease)
History of or active inflammatory bowel disease or active bowel inflammation
History of inflammatory bowel disease
Gastro-intestinal disease with increased risk of diarrhea (e.g. inflammatory bowel disease)
Gastrointestinal (GI) disease with increased risk of diarrhea [e.g. inflammatory bowel disease (IBD)]
Active inflammatory bowel disease or other bowel disease causing chronic diarrhea.
Patients with inflammatory or chronic functional bowel disorder, such as Crohn disease, inflammatory bowel disease, or gastrointestinal graft versus host disease that in the opinion of the investigator may interfere with absorption of ponatinib or increase the risk of serious complications
Have a history (within 3 years) of inflammatory bowel disease,
History of inflammatory bowel disease
History of or active inflammatory disease or active bowel inflammation
Severe gastrointestinal conditions such as clinical or radiological evidence of bowel obstruction within 4 weeks prior to study entry, uncontrolled diarrhea in the last 4 weeks prior to enrollment, or history of inflammatory bowel disease
Patients with gastrointestinal disease or disorder that could interfere with absorption of CUDC-907, such as bowel obstruction or inflammatory bowel disease
History of clinically significant Crohnâ€™s disease or inflammatory bowel disease (IBD)
Any history of inflammatory bowel disease
Prior history of inflammatory bowel disease or other chronic diarrheal illness
Clinically significant systemic infection or uncontrolled chronic inflammatory disease (eg, rheumatoid arthritis, inflammatory bowel disease) as determined by the investigator during screening.
Inflammatory bowel disease (IBD)/Crohn's
Patients with a history of gastric bypass surgery or inflammatory bowel disease
Prior colorectal surgery or history of inflammatory bowel disease
Any history of inflammatory bowel disease
Patients with inflammatory bowel disease
Diagnosis of inflammatory bowel disease, liver or kidney disease, bleeding diathesis
No history of Inflammatory bowel disease
Individuals with inflammatory bowel disease
Participants with dysplasia-associated mass or lesion (DALM) due to longstanding idiopathic inflammatory bowel disease will be excluded
Inflammatory bowel disease
Has severe colitis of any etiology or a history of inflammatory bowel disease (IBD)
Diagnosis of inflammatory bowel disease
Serious digestive and/or absorptive problems, including inflammatory bowel disease and chronic diarrhea that preclude adherence to the study diet.
Personal history of inflammatory bowel disease
History of CRC, bowel resection, polyposis syndrome, or inflammatory bowel disease
Contraindications to radiotherapy (including active inflammatory bowel disease).
Active inflammatory bowel disease within the last 6 months
Patients with active inflammatory bowel disease
Active inflammatory bowel disease within the last 6 months
Any active cancer, history of gastrointestinal cancer, or chronic disease such as peptic ulcer, irritable bowel syndrome, inflammatory bowel disease, intestinal malabsorption syndrome or other gastrointestinal disorder
Self-reported inflammatory bowel disease
No history of inflammatory bowel disease
History of inflammatory bowel disease
Has a history of inflammatory bowel disease or history of scleroderma
History of inflammatory bowel disease.
Active or history of inflammatory bowel disease (eg, colitis, Crohnâ€™s), irritable bowel disease, celiac disease or other serious gastrointestinal chronic conditions associated with diarrhea; active or history of systemic lupus erythematosus or Wegenerâ€™s granulomatosis
Active or history of inflammatory bowel disease (colitis, Crohnâ€™s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea; active or history of systemic lupus erythematosus or Wegenerâ€™s granulomatosis
Active or history of inflammatory bowel disease (colitis, Crohnâ€™s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea; active or history of systemic lupus erythematosus or Wegenerâ€™s granulomatosis
History of active or known autoimmune disease that can cause diarrhea like (but not limited to) Addison's disease, celiac disease/gluten intolerance/irritable bowel syndrome, scleroderma
Active or history of inflammatory bowel disease (colitis, Crohn's), diverticulitis, irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea; active or history of systemic lupus erythematosus or Wegener's granulomatosis
Active or history of inflammatory bowel disease (colitis, Crohnâ€™s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea; active or history of systemic lupus erythematosus or Wegenerâ€™s granulomatosis; currently receiving immunosuppressive doses of steroids or other immunosuppressive medications (inhaled and topical steroids are permitted)
History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin
History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin
History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin
Active or history of inflammatory bowel disease (colitis, Crohn's), celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea. Active or history of systemic lupus erythematosus or Wegener's granulomatosis.
History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin
Active gastrointestinal/malabsorption disorder at the discretion of the principal investigator\r\n* Inflammatory bowel disease\r\n* Celiac disease\r\n* Chronic pancreatitis\r\n* Chronic diarrhea or vomiting\r\n* Active eating disorder
History of inflammatory bowel disease, celiac disease, or other chronic gastrointestinal conditions associated with diarrhea or bleeding, or current acute colitis of any origin
Active or history of inflammatory bowel disease (colitis, Crohnâ€™s disease), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea
Active or history of inflammatory bowel disease (colitis, Crohn's), diverticulitis, irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea. Active or history of systemic lupus erythematosus or Wegener's granulomatosis.
Active or history of inflammatory bowel disease (colitis, Crohnâ€™s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea; active or history of systemic lupus erythematosus or Wegenerâ€™s granulomatosis
History of inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis), celiac disease, or other chronic gastrointestinal conditions associated with diarrhea, or current acute colitis of any origin
Active or history of inflammatory bowel disease (colitis, Crohnâ€™s), irritable bowel disease, celiac disease, or other serious, chronic, gastrointestinal conditions associated with diarrhea
Personal history of any chronic gastrointestinal (GI) disorder (i.e., irritable bowel syndrome, colitis)
Participant has >= grade 2 diarrhea (participants with grade 1 diarrhea are eligible provided stool for ova/parasites and stool cryptosporidium studies are negative)
Grade 2 or greater diarrhea of any cause at time of study entry
Uncontrolled nausea/vomiting/diarrhea;
Chronic diarrhea (excess of 2-3 stools/day above normal frequency).
Intractable, severe diarrhea, defined as > 1.500 cc diarrheal fluid per day, or diarrhea causing persistent severe electrolyte abnormalities, or hypoalbuminemia
Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease.
Diarrhea > grade 1 in the absence of antidiarrheals
Significant or recent gastrointestinal disorders with diarrhea as a major symptom (e.g. Crohn's disease, malabsorption, or complete blood count [CBC] grade >= 2 diarrhea of any etiology)
Uncontrolled chronic diarrhea > grade 2 at baseline.
Unresolved diarrhea ? CTCAE grade 2 or presence of medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease)
A history of chronic diarrhea, colitis, or intestinal perforation that in the opinion of the investigator precludes utilization of idelalisib
No currently active diarrhea that may affect the ability to absorb ZD6474
Chronic or acute GI disorders resulting in diarrhea of any severity grade.
Any CTCAE Grade 4 diarrhea (i.e., life-threatening consequences with urgent intervention indicated) within 7 days prior to Day 1
Any CTCAE Grade 2 or 3 diarrhea (i.e., increase of ? 4 stools per day over baseline), unless attributed to AdV, within 7 days prior to Day 1
Unresolved diarrhea >= Common Terminology Criteria for Adverse Events (CTCAE) grade 2 or a medical condition associated with chronic diarrhea (such as irritable bowel syndrome, inflammatory bowel disease)
Persistent >= grade 2 diarrhea regardless of etiology
History of acute diverticulitis within the last 6 months, or current chronic diarrhea
Diarrhea > grade 1 in the absence of antidiarrheals
Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohnâ€™s disease, malabsorption, or grade >= 2 [NCI CTCAE v.4.0] diarrhea of any etiology at screening)
Active treatment-refractory diarrhea that may affect the ability of the patient to absorb the trial agents or tolerate further diarrhea
History of symptomatic gastrointestinal disorder within the last five years resulting in bleeding or chronic or frequent diarrhea
Diarrhea > grade 1 in the absence of anti-diarrheals
Persistent greater than or equal to grade 2 diarrhea regardless of etiology.
Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
Ongoing GI adverse events > grade 2 (e.g., nausea, vomiting, or diarrhea) at the start of the study
No diarrhea >= grade 2 at baseline
Poorly-controlled diarrhea (> 4 loose bowel movement [BM]/day without use of anti-motility agents) within 7 days of study enrollment; patients may be reconsidered for the study if the diarrhea resolves
Patients with diarrhea >= CTCAE grade 2
No history of chronic diarrhea
Have a preexisting chronic condition resulting in persistent diarrhea.
Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.
Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.
Inability to swallow oral medications or a recent acute gastrointestinal disorder with diarrhea e.g., Cohn's disease, malabsorption, or Common Terminology Criteria for Adverse Event (CTCAE) Grade > 2 diarrhea of any etiology at baseline
Diarrhea ( >=3 loose bowel movements per day)
Duration of diarrhea of at least 1 week
Patients with diarrhea >= CTCAE grade 2
Uncontrolled diarrhea
Chronic diarrhea
Significant acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease,malabsorption, or CTCAE Grade ? 2 diarrhea of any etiology.
Diarrhea > grade 1 at baseline
Uncontrolled serious chronic gastrointestinal condition associated with diarrhea
Grade 2 or greater diarrhea
Patients with diarrhea >= CTCAE grade 2
Any gastrointestinal disorder with diarrhea as a major symptom, such as Crohnâ€™s, or pre-existing chronic diarrhea Common Terminology Criteria (CTC) grade >= 2 of any etiology; included are malabsorption disorders that in the opinion of the study physician may affect absorption of either afatinib or dasatinib
Active diarrhea >= CTCAE grade 2
Patients must not have significant gastrointestinal disorders with diarrhea as a major symptom (e.g. Crohnâ€™s disease, malabsorption, etc)
Subject has persistent diarrhea, malabsorption, or known sub-acute bowel obstruction ? NCI CTCAE Grade 2, despite medical management.
Active diarrhea of any grade
Have current or recent gastrointestinal disease with chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease.
Patients who have had grade 2 or higher diarrhea, despite optimal antidiarrheal supportive care, within 7 days prior to registration are not eligible
Persistent CTCAE v4.0 greater than or equal to grade 2 diarrhea regardless of etiology.
Uncontrolled chronic diarrhea ? grade 2 at baseline.
Persistent diarrhea or malabsorption ? NCI CTCAE grade 2, despite medical management.
Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom.
History of acute diverticulitis, or current chronic diarrhea
Patients must not have >= grade 2 diarrhea
Ongoing diarrhea defined as more than 1 watery stools/day.
Unresolved diarrhea ? CTCAE grade 2 or a medical condition associated with chronic diarrhea
Have a preexisting chronic condition resulting in persistent diarrhea.
Patients with uncontrolled diarrhea or persistent nausea/vomiting requiring daily antiemetic therapy for symptom management within the past 21 days
Participant has persistent diarrhea or clinically significant malabsorption syndrome or known sub-acute bowel obstruction ? Grade 2, despite medical management
Patients may not have the following co-morbid disease or concurrent illness:\r\n* Chronic or acute gastrointestinal (GI) disorders resulting in diarrhea of any severity grade; patients may not use chronic anti-diarrheal supportive care (more than 3 days/week) to control diarrhea in the 28 days prior to first dose of investigational drug (exception: anti-diarrheal medications used to control symptoms from a medication that will be discontinued prior to study are allowed with a 7 day washout before study therapy, for example loperamide for erlotinib-associated diarrhea)\r\n* Known cirrhosis, defined as Child Pugh class A or higher liver disease\r\n* Other malignancy undergoing active treatment\r\n* Any other severe/uncontrolled inter-current illness or significant co-morbid conditions that in the opinion of the investigator would impair study participation or cooperation
Patient has >= CTCAE grade 2 diarrhea
Patients with diarrhea >= CTCAE grade 2
Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management.
Patients with diarrhea >= CTCAE grade 2
Grade 2 or higher diarrhea at baseline unless deemed by the investigator to be caused by laxatives prescribed for symptomatic partial obstruction (e.g. MiraLAX)
Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn's disease, malabsorption, or Common Terminology Criteria for Adverse Events (CTCAE) grade > 2 diarrhea of any etiology
Significant chronic gastrointestinal disorder with diarrhea as a major symptom (e.g., Crohnâ€™s disease, malabsorption, or grade >= 2 diarrhea of any etiology screening)
Presence of chronic diarrhea (> grade 1 by Common Toxicity Criteria [CTC] criteria), short bowel syndrome, pancreatic insufficiency, or malabsorption
Patients with chronic or acute gastrointestinal (GI) disorders resulting in diarrhea of any severity grade; patients who are using chronic anti-diarrheal supportive care (more than 3 days/week) to control diarrhea in the 28 days prior to study entry
Patients with diarrhea CTCAE v4 grade >= 2
Patients with diarrhea >= CTCAE v4 grade 2
Unresolved diarrhea >= CTCAE (v4.0) grade 1
Patients with chronic or acute GI disorders resulting in diarrhea of any severity grade; patients who are using chronic anti-diarrheal supportive care (more than 3 days/week) to control diarrhea in the 28 days prior to enrollment
Any predisposing chronic condition resulting in baseline grade 2 or higher diarrhea
No uncontrolled diarrhea
Diarrhea ? Grade 2, impaired gastrointestinal absorption
Patients with grade 2 or greater diarrhea prior to study initiation despite maximal medical management due to medications or a medical condition such as Crohn's disease or malabsorption
Chronic diarrhea
History of gastrointestinal disease with diarrhea as the major symptom.
Significant gastrointestinal disorder with diarrhea as major symptom
Lower GI GvHD manifested by diarrhea must have other causes of diarrhea ruled out (eg, negative for Clostridium difficile or cytomegalovirus [CMV] infection or oral magnesium administration)
Patients with chronic diarrhea of grade 2 or greater despite maximal medical management.
Patients with diarrhea >= CTCAE grade 2
Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g. Crohn's disease, ulcerative colitis, malabsorption or Common Toxicity Criteria (CTC) grade >= 2 diarrhea of any etiology
Participants with history of chronic diarrhea, grade >= 2 prior to study participation; persons with up to grade 1 diarrhea will be eligible
Chronic diarrhea (loose, watery or frequent stools) at baseline
Current or recent (within 3 months of study drug administration) gastrointestinal disease such as chronic or intermittent diarrhea, or disorders that increase the risk of diarrhea, such as inflammatory bowel disease. Non-chronic conditions (e.g. infectious diarrhea) that are completely resolved for at least 2 weeks prior to starting study treatment are not exclusionary
Persistent diarrhea or malabsorption ? NCI CTCAE Grade 2, despite medical management
Patients who have had persistent GI GVHD manifested by diarrhea with stool volume < 500 mL/day in the absence of nausea or vomiting may be deemed as having Grade B GVHD if other causes of diarrhea have been ruled out (e.g., C. difficile or cytomegalovirus (CMV) infection, oral magnesium administration) and if the low stool volume reflects the effects of fasting or administration of narcotics or antidiarrheal medications.
Chronic or acute GI disorders resulting in diarrhea
Patients with diarrhea > CTCAE grade 2.
Patients with significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea
Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom for example Crohn's disease, malabsorption or Common Terminology Criteria (CTC) grade >= 2 diarrhea of any etiology
Patients with >= grade 2 or greater diarrhea despite maximal medical management due to medications or a medical condition such as Crohn's disease, malabsorption
Persistent diarrhea (>= Grade 2) lasting greater than (>) 3 days within 2 weeks before the first dose of study treatment.
Any gastrointestinal disorder with diarrhea as a major symptom, such as Crohn's, or pre- existing chronic diarrhea CTCAE Grade ? 2 of any etiology. Included are malabsorption disorders or surgical procedures that in the opinion of the investigator may affect absorption of study drug;
History of inflammatory colitides, chronic abdominal pain, or chronic diarrhea.
Chronic or acute GI disorders resulting in diarrhea
Patients with chronic diarrhea or with grade 2 or greater diarrhea despite maximal medical management.
Persistent diarrhea (greater than Grade 2) lasting > 3 days within 2 weeks before the first dose of study treatment
Uncontrolled nausea/vomiting/diarrhea;
Pre-existing diarrhea uncontrolled with supportive care; prior hemorrhagic diarrhea due to ulcerative colitis, inflammatory bowel disease or other cause; active, uncontrolled peptic ulcer disease even in the setting of proton-pump inhibitor or histamine2-blocker use
GI Tract: biopsy showing amyloid deposition along with symptoms such as GI bleeding or persistent diarrhea (> 4 loose stools/day) Autonomic or Peripheral Nervous System: defined as orthostasis, symptoms of nausea or dysgeusia, recurrent diarrhea or constipation, abnormal sensory and/or motor findings on neurologic exam, or gastric atony by gastric emptying scan
Current diarrhea >= CTCAE grade 2
Subjects may not have ongoing chronic diarrhea
Significantly diseased or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea.
Diarrhea (> Grade 1)
Has diarrhea (> Grade 1)
Patients with diarrhea >= CTCAE grade 2
Patients with diarrhea > CTCAE grade 1
Subject must have NCI common toxicity Grade 3-4 immune-related diarrhea for up to 3 days or persistent Grade 2 diarrhea for more than 5 days
Known malabsorption syndrome, short bowel or chologenic diarrhea not controlled by specific therapeutic means
Chronic diarrhea or malabsorptive diseases (e.g., Crohnâ€™s disease)
Diarrhea associated with C. difficile positive stool assay
Other known etiology of diarrhea (e.g. other enteric pathogen, other intestinal disease)
>= Grade 3 diarrhea, >= grade 3 rectal bleeding, abdominal cramping, or incontinence of stool =< 7 days prior to registration
Planned use of leucovorin (because of the risk of secretory diarrhea)
Chronic diarrhea
Persistent diarrhea or malabsorption despite medical management.
Currently active diarrhea that may affect the ability of the patient to absorb the ZD6474 or tolerate diarrhea
Patients must not have persistent diarrhea greater than National Cancer Institute (NCI) CTCAE grade 2 at the time of study registration, despite medical management
Patients with active diarrhea > CTCAE v4.03 grade 2
Diarrhea or clinical concern for C. difficile infection
Diarrhea symptoms resolved to Grade 1 or better.
Known history of colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis.
Known history of colitis, inflammatory bowel disease, pneumonitis, or pulmonary fibrosis.
Current acute or chronic colitis, inflammatory bowel disease, pneumonitis or pulmonary fibrosis.
Other severe acute or chronic medical conditions including colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis, severe Chronic obstructive pulmonary disease (COPD) requiring > 3 hospitalization in the past year
Current severe acute or chronic colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis
Severe (requiring active treatment) acute or chronic medical conditions including: colitis, inflammatory bowel disease, pneumonitis, or pulmonary fibrosis
All other significant diseases (for example, colitis, pneumonitis, pulmonary fibrosis, inflammatory bowel disease, uncontrolled asthma)
Known history of autoimmune colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis;
Known history of immune-mediated colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis.
Known history of immune mediated colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis.
Known history of colitis, inflammatory bowel disease, pneumonitis, or pulmonary fibrosis
